Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M601252200 on April 4, 2006

J. Biol. Chem., Vol. 281, Issue 23, 15694-15700, June 9, 2006
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
281/23/15694    most recent
M601252200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhang, X.
Right arrow Articles by Ornitz, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhang, X.
Right arrow Articles by Ornitz, D. M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Receptor Specificity of the Fibroblast Growth Factor Family

THE COMPLETE MAMMALIAN FGF FAMILY*

Xiuqin Zhang{ddagger}, Omar A. Ibrahimi§, Shaun K. Olsen§, Hisashi Umemori, Moosa Mohammadi§, and David M. Ornitz{ddagger}1

From the {ddagger}Department of Molecular Biology and Pharmacology, Washington University School of Medicine, St. Louis, Missouri 63110, §Department of Pharmacology, New York University School of Medicine, New York, New York 10016, Department of Biological Chemistry, Molecular & Behavioral Neuroscience Institute, University of Michigan Medical School, Ann Arbor, Michigan 48109

Received for publication, February 8, 2006 , and in revised form, April 3, 2006.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
In mammals, fibroblast growth factors (FGFs) are encoded by 22 genes. FGFs bind and activate alternatively spliced forms of four tyrosine kinase FGF receptors (FGFRs 1–4). The spatial and temporal expression patterns of FGFs and FGFRs and the ability of specific ligand-receptor pairs to actively signal are important factors regulating FGF activity in a variety of biological processes. FGF signaling activity is regulated by the binding specificity of ligands and receptors and is modulated by extrinsic cofactors such as heparan sulfate proteoglycans. In previous studies, we have engineered BaF3 cell lines to express the seven principal FGFRs and used these cell lines to determine the receptor binding specificity of FGFs 1–9 by using relative mitogenic activity as the readout. Here we have extended these semiquantitative studies to assess the receptor binding specificity of the remaining FGFs 10–23. This study completes the mitogenesis-based comparison of receptor specificity of the entire FGF family under standard conditions and should help in interpreting and predicting in vivo biological activity.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Fibroblast growth factors (FGFs)2 comprise a structurally related family of 22 molecules. FGFs can be grouped into seven subfamilies based on their sequence similarities and functional properties (1–3). FGFs bind four high affinity, ligand-dependent FGF receptor tyrosine kinase molecules (FGFR1–4). In the presence of heparan sulfate (HS) glycosaminoglycans, FGFs stably bind FGFRs and lead to the formation of 2:2:2 FGF-FGFR-HS dimers, which enables the cytoplasmic kinase domains to transphosphorylate one another and become activated (4). FGFR activation results in the stimulation of various signal transduction cascades that have been implicated in multiple aspects of vertebrate and invertebrate embryonic development, tumor growth, angiogenesis, wound healing, and physiology (2, 5–7).

Each FGFR contains an extracellular ligand binding domain, a single transmembrane domain, and an intracellular tyrosine kinase domain. The extracellular ligand binding domain of the FGFR contains two or three Ig-like domains (8, 9). Alternative RNA splicing that utilizes one of two unique exons results in two different versions of Ig-like domain III (referred to as domains IIIb and IIIc) in FGFRs 1–3. This alternative splicing is an essential determinant of ligand binding specificity (10–14). The IIIa ("a") splice form encodes a secreted extracellular FGF-binding protein with no known signaling capability (13). The IIIb ("b") and IIIc ("c") splice forms are regulated in a tissue-specific manner, such that the b isoform is restricted to epithelial lineages and the c isoform is preferentially expressed in mesenchymal lineages (15–18). This tissue specificity is particularly important for FGFR2 function. The structural basis by which this major alternative splicing in Ig-like domain III of FGFR2 modulates FGF binding specificity has been elucidated (14). In addition to tissue-specific FGF and FGFR expression, FGFR activation is modulated by heparin, heparan sulfate, or other glycosaminoglycan chains (19–23). Importantly, tissue-specific alterations in glycosaminoglycan structure provide a mechanism to modulate FGF signaling (24–27). It has been recently postulated that the HS selectivity in FGF signaling is attained in the context of a 2:2 FGF-FGFR dimer and not by FGF, FGFR, or even 1:1 FGF-FGFR pairs (28).

The identification of FGF-FGFR binding specificities is critical to understanding the biological mechanisms involved in normal development and pathogenesis. Here we extend our previous study (12) to semiquantitatively compare the activity of all signaling members of the FGF family on the major splice forms of all FGFRs.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Materials—Human recombinant FGF1, FGF7, FGF8, FGF9, FGF10, FGF16, FGF17, FGF18, and FGF20 were from PeproTech Inc. (Rocky Hill, NJ). Recombinant human FGF12, FGF14, FGF19, FGF21, and FGF23 were expressed in Escherichia coli and purified as previously described (29–31). The source of FGFR cDNAs, FGFR expression plasmids, and FGFR-expressing BaF3 cell lines were described previously (12).

BaF3 Cell Culture and Mitogenic Assay—BaF3 cells expressing specific FGFRs were described previously (12). Cells were maintained in RPMI 1640 medium (Sigma) supplemented with 10% newborn bovine serum (Sigma), 0.5 ng/ml murine-recombinant interleukin-3 (PeproTech Inc.), 2 mM L-glutamine, penicillin-streptomycin, 50 nM beta-mercaptoethanol (BaF3 culture medium), and G418 (600 µg/ml).

For mitogenic assays, FGFR-expressing BaF3 cells were plated at a density of 30,000 cells/well in a 96-well assay plate in BaF3 assay medium containing varying concentrations of FGF and heparin. FGFs diluted in assay medium were added to each well for a total volume of 200 µl/well. The cells were then incubated for 36–48 h. Mitogenic activity was determined by adding 1 µCi of [3H]thymidine in 50 µl of BaF3 assay medium to each well. The cells were harvested after 4–6 h by filtration through glass fiber paper. The incorporated [3H]thymidine was counted on a Wallac beta plate scintillation counter (PerkinElmer Life Sciences).


Figure 1
View larger version (26K):
[in this window]
[in a new window]
  		FIGURE 1.
Receptor activation by FGFs 7, 10, and 22. A, FGF22 expression in BHK cells stably transfected with expression plasmid APtag5-FGF22 (BHK/ATtag5-FGF22) or empty vector APtag5 (BHK/APtag5). Individual Zeocin-resistant clones were selected and screened by reverse transcription-PCR for Fgf22 expression. Lane 1, wild-type BHK cells do not express FGF22; lane 2, BHK cells transfected with the APtag5 plasmid do not express FGF22; lane 3, BHK cells transfected with APtag5-FGF22 express high levels of FGF22. B, BaF3 cell mitogenic assay for c-spliced FGFRs. C, BaF3 cell mitogenic assay for b-spliced FGFRs and FGFR4{Delta}. CM, conditioned medium.

 
Preparation of FGF22-conditioned Medium—A cDNA encoding the full-length mouse FGF22 protein was isolated from mouse brain mRNA by reverse transcription-PCR (forward primer, 5'-AATTGCTAGCATGCGCAGCCGCCTCTGGCTG-3'; reverse primer, 5'-AGGCCTCGAGAGACGAGACCAAGACTGGCAG-3') (32). The PCR product (~500 bp) was inserted into the NheI-XhoI sites of the APtag5 vector (GenHunter Inc.), replacing both the signal sequence and the alkaline phosphatase sequence. APtag5-mFGF22 or the APtag5 empty vector was transfected into baby hamster kidney (BHK) cells (cultured in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum, 2 mM L-glutamine, and penicillin/streptomycin). The cells were replated at 80–90% confluence into 90-mm dishes the day before transfection and then were transfected with 24 µg of plasmid and 60 µl of Lipofectamine 2000 in 1.5 ml of Opti-MEM (Invitrogen) medium according to the manufacturer's directions. After 48 h, the cells were split 1:20 into Dulbecco's modified Eagle's medium containing 10% fetal bovine serum, 2 mM L-glutamine, penicillin/streptomycin, and 500 µg/ml Zeocin (Invitrogen). Isolated colonies were picked after 10–14 days and propagated in the same medium. Reverse transcription-PCR (forward primer, 5'-GCTTCTATGTGGCCATGAATCGCA-3'; reverse primer, 5'-AGACCAAGACTGGCAGGAAGTGT-3') was used to identify stable clonal cell lines expressing high levels of Aptag5-FGF22 (see Fig. 1A).

Subconfluent stably transfected cell lines, grown in selection medium, were washed twice with phosphate-buffered saline and allowed to grow in BaF3 assay medium containing 2 µg/ml heparin for 48–72 h. Conditioned medium from control APtag-5 cells and Aptag5-FGF22 cells was collected, centrifuged to remove debris, and used for subsequent BaF3 assays.

Data Analysis—FGF1 was used as a positive control to normalize the mitogenic activity of the other FGFs. To reduce sampling error in the comparison of the relative mitogenic activity, the mitogenic activity for each ligand was averaged at two different concentrations (312 and 1250 pM) (see Table 1) and normalized to the activity of FGF1 at these concentrations, or in the case of FGF19, -21, -23 to 5 nM FGF1.


View this table:
[in this window]
[in a new window]
  		TABLE 1
Relative mitogenic activity of FGF subfamilies

 

   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
Receptor Binding Specificity of FGF Subfamilies—The murine pro-B cell line, BaF3, is an interleukin-3-dependent cell line that is commonly used for the analyses of receptor tyrosine kinase activity. Wild-type BaF3 cells do not express FGFRs, and BaF3 cells transfected with FGFRs proliferate in the absence of interleukin-3 when stimulated with FGF and heparin (19). Receptor binding specificity for FGFs 1–9 has been previously described (12). To directly compare the activity of FGF subfamilies containing newly described members, all seven FGFR-expressing BaF3 cell lines were assayed with each FGF at concentrations ranging from 20 to 5000 pM (FGFs 1, 7–10, 16–18, and 20) and from 3 to 800 nM (FGFs 19, 21, and 23).


Figure 2
View larger version (21K):
[in this window]
[in a new window]
  		FIGURE 2.
Receptor activation by FGFs 8, -17, and -18. A, BaF3 cell mitogenic assay for c-spliced FGFRs. B, BaF3 cell mitogenic assay for b-spliced FGFRs and FGFR4{Delta}.

 
FGFs 7, 10, and 22 are more closely related to each other by sequence than to any other FGF and were predicted to have similar activity toward FGFRs. We and others have failed to produce active recombinant FGF22 protein. We therefore developed a cell line that secretes FGF22 into the culture medium (Fig. 1A). Dilutions of conditioned medium were assayed on FGFR2b-BaF3 cells. The concentration of the FGF22-conditioned medium was estimated to be equivalent to an FGF10 concentration of 300–600 pM. Control-conditioned medium showed no activity toward any of the BaF3 cell lines. FGFs 7, 10, and 22 all strongly activated FGFR2b. FGFs 10 and 22 showed weak activity toward FGFR1b, and all three of these FGFs failed to activate any of the other FGFR-expressing cell lines (Fig. 1, B and C; Fig. 5; and Table 1).

The FGFs 8, 17, and 18 subfamily members showed similar activities to each other as those previously described (33, 34). These FGFs specifically activated FGFRs 1c, 2c, and 3c and the two Ig-like domain forms of FGFR4 (4{Delta}). FGF8 subfamily members showed higher relative activity on FGFR3c cells and less activity toward FGFR1c. No activity was observed on the FGFRb isoform-expressing cell lines (Figs. 2 and 5 and Table 1).

The FGFs 9, 16, and 20 subfamily members showed a similar profile to that of FGF9 (12, 35). These FGFs activated FGFRc isoforms and FGFR4 with high activity, and unlike other FGFs that preferentially activate c splice form receptors, these FGFs consistently showed activity toward FGFR3b-expressing cells. FGF20 showed slight activity on FGFR2b cells and no activity on FGFR1b cells. FGFs 9 and 16 showed no activity toward FGFR1b or -2b (Figs. 3 and 5 and Table 1).

The FGF19 (mouse FGF15), FGF21, and FGF23 subfamily is unique in that these FGFs can behave as secreted hormones (36–41). To obtain significant activity of these FGFs on FGFR-expressing BaF3 cells required a protein concentration ranging from 3 to 800 nM and a heparin concentration >10 µg/ml (Fig. 4A). These parameters indicated low relative activity compared with other classic members of the FGF family. However, at these concentrations, FGFs 19, 21, and 23 showed consistent activity toward FGFR1c, 2c, 3c, and FGFR4 but no activity toward FGFR1b, 2b, or 3b (Fig. 4, C and D; Fig. 5; and Table 1).

The FGF11 family has no known activity toward any FGFR (30, 42, 43). Recombinant FGF12 and FGF14 protein showed no activity on any of the FGFR-expressing BaF3 cell lines, consistent with previous observations (30) (data not shown).


   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
The FGF family is one of the largest growth factor families, consisting of 22 members sharing 13–71% sequence similarity in mammals (2). FGFs possess a large range of activities in embryonic development and physiological functions in the adult. In the embryo, FGFs often signal across mesenchymal-epithelial boundaries, where they regulate organogenesis and pattern formation (44–47). In the adult, FGFs play important roles in regulating homeostasis, wound healing, and tissue repair (48). Unregulated expression of FGFs can cause cancer (41, 49, 50).


Figure 3
View larger version (22K):
[in this window]
[in a new window]
  		FIGURE 3.
Receptor activation by FGFs 9, 16, and 20. A, BaF3 cell mitogenic assay for c-spliced FGFRs. B, BaF3 cell mitogenic assay for b-spliced FGFRs and FGFR4{Delta}.

 
The expression patterns of FGF receptors 1, 2, and 3 are distinct but overlap in some tissues. Analysis of the alternative splicing pattern of these receptors demonstrates that the utilization of either the b or c exon is dependent upon cell lineage. The b isoform is preferentially expressed in epithelial tissues, whereas the c isoform is expressed in mesenchymal tissues (17, 51–53). The activity of several of the FGFs can be divided along these lines. For example, the FGF7 subfamily is expressed in mesenchyme and shows the greatest activity toward FGFR2b. The FGF8 subfamily is expressed in epithelial tissues and activates c splice forms of FGFRs. Binding specificity between FGF and FGFRs is thus critical for the spatial regulation of FGF signaling.

The specificity of the FGF7 subfamily, demonstrated in vitro in the BaF3 cell assay (Fig. 5), closely reflects the in vivo function of FGF10, a molecule expressed in mesenchymal tissue that signals to epithelial FGFR2b. Disruption of FGF10 signaling is catastrophic to embryonic development, resulting in severe defects in limb development and in organs requiring branching morphogenesis, such as the pancreas, salivary glands, and lungs (54–60). The interaction between FGF10 and FGFR2b is also required for embryonic palate and cecum development (61, 62). Mutations in FGFR2 that alter ligand binding specificity also result in developmental disease. Apert syndrome is a debilitating disease involving craniosynostosis, syndactyly, and mental retardation (63–65). The molecular etiology of Apert syndrome stems from inappropriate activation of mesenchymal FGFR2c by FGF7 family members (31, 66–69).

The crystal structure of FGF10 in complex with FGFR2b has revealed that specific contacts between residues from the alternatively spliced betaC'–betaE loop region of FGFR2b and residues in the beta4 strand and N terminus of FGF10 account for the FGF10-FGFR2b binding specificity (14). In particular, two highly specific hydrogen bonds involving Asp-76 in the N terminus of FGF10 and Ser-315 in the betaC'–betaE loop of FGFR2b are essential for FGF10-FGFR2b specificity. The involvement of these hydrogen bonds in conferring specificity between the FGF7 subfamily and FGFR2b is further supported by the fact that Asp-76 is unique to the FGF7 subfamily and Ser-315 is located in the b splice isoform-specific betaC'–betaE loop (14).

FGF8 subfamily members exclusively bind FGFRc splice forms and FGFR4 (Fig. 5). The recent crystal structure of FGF8b in complex with FGFR2c has provided the molecular basis by which FGF8 subfamily members attain their specificity/promiscuity toward c splice isoforms of FGFRs 1–3 and FGFR4 (70). Importantly, in the case of the FGF8 subfamily, the alternatively spliced betaF and betaG strands, and not the betaC'–betaE loop, harbor the primary receptor determinants of FGF8 subfamily binding specificity. This is because the spatial positioning of the N terminus of FGF8 subfamily members, relative to the beta-trefoil core, is opposite to that of other FGFs (70).

FGFs 8, 17, and 18 have distinct and overlapping expression patterns in several tissues, such as the developing mid-hindbrain junction (71–73). Several of these FGFs are required for central nervous system morphogenesis (33, 70, 74–76). Fgf8 and Fgf17 are expressed in the apical ectodermal ridge during limb development, and inactivation of Fgf8 in early limb ectoderm causes a reduction in limb-bud size, demonstrating that FGF8 signaling from the apical ectodermal ridge is essential for normal limb development (77). Fgf18 is expressed in the perichondrium, where it regulates chondrogenesis and osteogenesis (78, 79).

The FGF9 subfamily activates all FGFRc isoforms and FGFR3b (Fig. 5). FGF9 is widely expressed in epithelial-like and neuronal tissues during embryonic development and is required for lung, heart, inner ear, digestive system, and testes development (35, 80–88). In the BaF3 mitogenic assay, FGF19 subfamily members have weak activity compared with FGF1. However, at high concentrations, these FGFs activate FGFR1c, -2c, -3c, and FGFR4 (Fig. 5). Compared with other FGF subfamilies that have high affinities for FGFRs and regulate cell proliferation, differentiation, and migration, these subfamily members appear to serve as metabolic regulators and hormones (36, 37, 40, 89–94). It is possible that other cofactors are required for optimal activity or that these FGFs interact with and activate other types of receptors. Recently, the Klotho protein was found to serve as a coreceptor for FGF23 binding to FGFR1c, -3c, and -4, and in signaling assays, Klotho enhanced FGF23 activity over 10-fold (95). Additionally, kidney epithelial cells may express an FGF23 receptor on their basolateral surface that is functionally distinct from known FGFRs (96).


Figure 4
View larger version (27K):
[in this window]
[in a new window]
  		FIGURE 4.
Receptor activation by FGFs 19, 21, and 23. A, heparin dose response for FGFs 19, 21, and 23 measured on FGFR1c-expressing BaF3 cells. Activity increases with increasing heparin but appears to plateau at concentrations >10 µg/ml. B, FGF1 control activity used to normalize the activity of FGFs 19, 21, and 23. C, BaF3 cell mitogenic assay for c-spliced FGFRs. D, BaF3 cell mitogenic assay for b-spliced FGFRs and FGFR4{Delta}.

 


Figure 5
View larger version (30K):
[in this window]
[in a new window]
  		FIGURE 5.
Diagram showing relative activity of FGFs grouped by subfamilies. *, data from Ornitz et al. (12); #, not tested.

 
As previously reported, FGFs 12 and 14 showed no mitogenic activity in the BaF3 assay (Fig. 5) (30). The FGF11–14 subfamily, also termed FGF homologous factors (FHFs), contain sequence homology to the core region of FGFs (97–100). Indeed, the crystal structure of FHF1b (FGF12b) shows that the core region of FHFs superimpose very well onto that of bona fide FGFs such as FGF9 (30). The structure shows that two FHF-invariant surface residues in the core region of FHFs, Arg-52 in the beta4–beta5 loop and Val-95 in the beta9 strand of FHF1b, contribute to the inability of FHFs to bind FGFRs (30). FHFs differ from most other FGFs in that they lack an N-terminal signal sequence. FHFs are expressed at highest levels in the developing and mature nervous system (100, 101) where they are important for neurophysiological function (102–104). Interestingly, members of the FHF family have been found to interact with cytoplasmic proteins, such as IB2, and the C-terminal tail of voltage-gated sodium channels (42, 43, 105–109).

FGF1 is the universal FGF and can activate all FGFRs. Comparison of the crystal structures of FGF1-FGFR1c, FGF1-FGFR2c, and FGF1-FGFR3c complexes has provided key insights into the unique FGFR binding promiscuity of FGF1 (110). FGF1 was used as an internal control to normalize the relative activity of other FGFs. The diversity of FGF receptor binding specificity is summarized in Table 1 and Fig. 5. The relative activity of these FGFs can be affected by the quality of the recombinant protein and may account for quantitative differences between the data shown here and that described previously using the same assay (12). A quantitative systematic analysis of all possible FGF-FGFR binding interactions is being carried out by Mohammadi et al. (4) using surface plasmon resonance (see Table 1 in Ref. 4). Overall, the currently available surface plasmon resonance data are in agreement with the results of the mitogenesis-based analysis presented here. The few differences between these data sets may be due to the fact that the surface plasmon resonance experiments are carried out in the absence of heparin/HS to solely monitor 1:1 FGF-FGFR binding, whereas the mitogenic assays are in the presence of exogenous heparin.

The in vivo specificity of FGFs may also diverge from these in vitro data as, in vivo, many cofactors may modulate FGF affinity for FGFRs. Additionally, the possibility of heterodimer formation between FGFs and FGFRs may further increase the repertoire of receptor-ligand interactions. With these caveats in mind, the data shown here, assayed under identical experimental conditions, should provide a base line for comparison of relative FGF activity and specificity and should allow predictions of potential signaling between FGF ligands and FGF receptors in development, in tissue homeostasis, and in disease.


   FOOTNOTES
 
* This work was funded by National Institutes of Health Grants HL076664 (to D. M. O.) and DE013686 (to M. M.), a grant from the March of Dimes foundation, and a contribution from the Virginia Friedhofer Charitable Trust (to D. M. O.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

This is paper II in a series. Paper I is Ref. 12. Back

1 To whom correspondence should be addressed: Dept. of Molecular Biology and Pharmacology, Washington University School of Medicine, Campus Box 8103, 660 S. Euclid Ave., St. Louis, MO 63110. E-mail: dornitz{at}wustl.edu.

2 The abbreviations used are: FGF, fibroblast growth factor; FGFR, FGF receptor; HS, heparan sulfate; BHK, baby hamster kidney; FHF, FGF homologous factor. Back


   ACKNOWLEDGMENTS
 
We thank Ling Li for technical assistance.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Itoh, N., and Ornitz, D. M. (2004) Trends Genet. 20, 563–569[CrossRef][Medline] [Order article via Infotrieve]
  2. Ornitz, D. M., and Itoh, N. (2001) Genome Biol. 2, Reviews 3005
  3. Popovici, C., Roubin, R., Coulier, F., and Birnbaum, D. (2005) BioEssays 27, 849–857[CrossRef][Medline] [Order article via Infotrieve]
  4. Mohammadi, M., Olsen, S. K., and Ibrahimi, O. A. (2005) Cytokine Growth Factor Rev. 16, 107–137[CrossRef][Medline] [Order article via Infotrieve]
  5. McKeehan, W. L., Wang, F., and Kan, M. (1998) Prog. Nucleic Acid Res. Mol. Biol. 59, 135–176[Medline] [Order article via Infotrieve]
  6. Ornitz, D. M., and Marie, P. J. (2002) Genes Dev. 16, 1446–1465[Free Full Text]
  7. Powers, C. J., McLeskey, S. W., and Wellstein, A. (2000) Endocr. Relat. Cancer 7, 165–197[Abstract]
  8. Lee, P. L., Johnson, D. E., Cousens, L. S., Fried, V. A., and Williams, L. T. (1989) Science 245, 57–60[Abstract/Free Full Text]
  9. Johnson, D. E., and Williams, L. T. (1993) Adv. Cancer Res. 60, 1–41[Medline] [Order article via Infotrieve]
  10. Chellaiah, A. T., McEwen, D. G., Werner, S., Xu, J., and Ornitz, D. M. (1994) J. Biol. Chem. 269, 11620–11627[Abstract/Free Full Text]
  11. Johnson, D. E., Lu, J., Chen, H., Werner, S., and Williams, L. T. (1991) Mol. Cell. Biol. 11, 4627–4634[Abstract/Free Full Text]
  12. Ornitz, D. M., Xu, J., Colvin, J. S., McEwen, D. G., MacArthur, C. A., Coulier, F., Gao, G., and Goldfarb, M. (1996) J. Biol. Chem. 271, 15292–15297[Abstract/Free Full Text]
  13. Duan, D. S., Werner, S., and Williams, L. T. (1992) J. Biol. Chem. 267, 16076–16080[Abstract/Free Full Text]
  14. Yeh, B. K., Igarashi, M., Eliseenkova, A. V., Plotnikov, A. N., Sher, I., Ron, D., Aaronson, S. A., and Mohammadi, M. (2003) Proc. Natl. Acad. Sci. U. S. A. 100, 2266–2271[Abstract/Free Full Text]
  15. Alarid, E. T., Rubin, J. S., Young, P., Chedid, M., Ron, D., Aaronson, S. A., and Cunha, G. R. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 1074–1078[Abstract/Free Full Text]
  16. Gilbert, E., Del Gatto, F., Champion-Arnaud, P., Gesnel, M. C., and Breathnach, R. (1993) Mol. Cell. Biol. 13, 5461–5468[Abstract/Free Full Text]
  17. Orr-Urtreger, A., Bedford, M. T., Burakova, T., Arman, E., Zimmer, Y., Yayon, A., Givol, D., and Lonai, P. (1993) Dev. Biol. 158, 475–486[CrossRef][Medline] [Order article via Infotrieve]
  18. Yan, G., Fukabori, Y., McBride, G., Nikolaropolous, S., and McKeehan, W. L. (1993) Mol. Cell. Biol. 13, 4513–4522[Abstract/Free Full Text]
  19. Ornitz, D. M., Yayon, A., Flanagan, J. G., Svahn, C. M., Levi, E., and Leder, P. (1992) Mol. Cell. Biol. 12, 240–247[Abstract/Free Full Text]
  20. Yayon, A., Klagsbrun, M., Esko, J. D., Leder, P., and Ornitz, D. M. (1991) Cell 64, 841–848[CrossRef][Medline] [Order article via Infotrieve]
  21. Rapraeger, A. C., Krufka, A., and Olwin, B. B. (1991) Science 252, 1705–1708[Abstract/Free Full Text]
  22. Penc, S. F., Pomahac, B., Winkler, T., Dorschner, R. A., Eriksson, E., Herndon, M., and Gallo, R. L. (1998) J. Biol. Chem. 273, 28116–28121[Abstract/Free Full Text]
  23. Taylor, K. R., Rudisill, J. A., and Gallo, R. L. (2005) J. Biol. Chem. 280, 5300–5306[Abstract/Free Full Text]
  24. Allen, B. L., Filla, M. S., and Rapraeger, A. C. (2001) J. Cell Biol. 155, 845–858[Abstract/Free Full Text]
  25. Allen, B. L., and Rapraeger, A. C. (2003) J. Cell Biol. 163, 637–648[Abstract/Free Full Text]
  26. Ornitz, D. M. (2000) BioEssays 22, 108–112[CrossRef][Medline] [Order article via Infotrieve]
  27. Perrimon, N., and Bernfield, M. (2000) Nature 404, 725–728[CrossRef][Medline] [Order article via Infotrieve]
  28. Mohammadi, M., Olsen, S. K., and Goetz, R. (2005) Curr. Opin. Struct. Biol.
  29. Yu, X., Ibrahimi, O. A., Goetz, R., Zhang, F., Davis, S. I., Garringer, H. J., Linhardt, R. J., Ornitz, D. M., Mohammadi, M., and White, K. E. (2005) Endocrinology 146, 4647–4656[Abstract/Free Full Text]
  30. Olsen, S. K., Garbi, M., Zampieri, N., Eliseenkova, A. V., Ornitz, D. M., Goldfarb, M., and Mohammadi, M. (2003) J. Biol. Chem. 278, 34226–34236[Abstract/Free Full Text]
  31. Ibrahimi, O. A., Zhang, F., Eliseenkova, A. V., Itoh, N., Linhardt, R. J., and Mohammadi, M. (2004) Hum. Mol. Genet. 13, 2313–2324[Abstract/Free Full Text]
  32. Umemori, H., Linhoff, M. W., Ornitz, D. M., and Sanes, J. R. (2004) Cell 118, 257–270[CrossRef][Medline] [Order article via Infotrieve]
  33. Xu, J. S., Liu, Z. H., and Ornitz, D. M. (2000) Development (Camb.) 127, 1833–1843[Abstract]
  34. Moon, A. M., Guris, D. L., Seo, J. H., Li, L., Hammond, J., Talbot, A., and Imamoto, A. (2006) Dev. Cell 10, 71–80[CrossRef][Medline] [Order article via Infotrieve]
  35. Santos-Ocampo, S., Colvin, J. S., Chellaiah, A. T., and Ornitz, D. M. (1996) J. Biol. Chem. 271, 1726–1731[Abstract/Free Full Text]
  36. Inagaki, T., Choi, M., Moschetta, A., Peng, L., Cummins, C. L., McDonald, J. G., Luo, G., Jones, S. A., Goodwin, B., Richardson, J. A., Gerard, R. D., Repa, J. J., Mangelsdorf, D. J., and Kliewer, S. A. (2005) Cell Metab. 2, 217–225[CrossRef][Medline] [Order article via Infotrieve]
  37. Kharitonenkov, A., Shiyanova, T. L., Koester, A., Ford, A. M., Micanovic, R., Galbreath, E. J., Sandusky, G. E., Hammond, L. J., Moyers, J. S., Owens, R. A., Gromada, J., Brozinick, J. T., Hawkins, E. D., Wroblewski, V. J., Li, D. S., Mehrbod, F., Jaskunas, S. R., and Shanafelt, A. B. (2005) J. Clin. Investig. 115, 1627–1635[CrossRef][Medline] [Order article via Infotrieve]
  38. White, K. E., Carn, G., Lorenz-Depiereux, B., Benet-Pages, A., Strom, T. M., and Econs, M. J. (2001) Kidney Int. 60, 2079–2086[CrossRef][Medline] [Order article via Infotrieve]
  39. Riminucci, M., Collins, M. T., Fedarko, N. S., Cherman, N., Corsi, A., White, K. E., Waguespack, S., Gupta, A., Hannon, T., Econs, M. J., Bianco, P., and Gehron Robey, P. (2003) J. Clin. Investig. 112, 683–692[CrossRef][Medline] [Order article via Infotrieve]
  40. Yu, X., and White, K. E. (2005) Cytokine Growth Factor Rev. 16, 221–232[CrossRef][Medline] [Order article via Infotrieve]
  41. Ezzat, S., and Asa, S. L. (2005) Horm. Metab. Res. 37, 355–360[CrossRef][Medline] [Order article via Infotrieve]
  42. Goldfarb, M. (2005) Cytokine Growth Factor Rev. 16, 215–220[CrossRef][Medline] [Order article via Infotrieve]
  43. Schoorlemmer, J., and Goldfarb, M. (2001) Curr. Biol. 11, 793–797[CrossRef][Medline] [Order article via Infotrieve]
  44. Boilly, B., Vercoutter-Edouart, A. S., Hondermarck, H., Nurcombe, V., and Le Bourhis, X. (2000) Cytokine Growth Factor Rev. 11, 295–302[CrossRef][Medline] [Order article via Infotrieve]
  45. Ornitz, D. M. (2005) Cytokine Growth Factor Rev. 16, 205–213[CrossRef][Medline] [Order article via Infotrieve]
  46. Huang, P., and Stern, M. J. (2005) Cytokine Growth Factor Rev. 16, 151–158[CrossRef][Medline] [Order article via Infotrieve]
  47. Thisse, B., and Thisse, C. (2005) Dev. Biol. 287, 390–402[Medline] [Order article via Infotrieve]
  48. Finch, P. W., and Rubin, J. S. (2004) Adv. Cancer Res. 91, 69–136[Medline] [Order article via Infotrieve]
  49. Grose, R., and Dickson, C. (2005) Cytokine Growth Factor Rev. 16, 179–186[CrossRef][Medline] [Order article via Infotrieve]
  50. Dailey, L., Ambrosetti, D., Mansukhani, A., and Basilico, C. (2005) Cytokine Growth Factor Rev. 16, 233–247[CrossRef][Medline] [Order article via Infotrieve]
  51. Goldstrohm, A. C., Greenleaf, A. L., and Garcia-Blanco, M. A. (2001) Gene (Amst.) 277, 31–47[CrossRef][Medline] [Order article via Infotrieve]
  52. Beer, H. D., Vindevoghel, L., Gait, M. J., Revest, J. M., Duan, D. R., Mason, I., Dickson, C., and Werner, S. (2000) J. Biol. Chem. 275, 16091–16097[Abstract/Free Full Text]
  53. Wuechner, C., Nordqvist, A. C., Winterpacht, A., Zabel, B., and Schalling, M. (1996) Int. J. Dev. Biol. 40, 1185–1188[Medline] [Order article via Infotrieve]
  54. Miralles, F., Czernichow, P., Ozaki, K., Itoh, N., and Scharfmann, R. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 6267–6272[Abstract/Free Full Text]
  55. Ye, F., Duvillie, B., and Scharfmann, R. (2005) Diabetologia 48, 277–281[CrossRef][Medline] [Order article via Infotrieve]
  56. Steinberg, Z., Myers, C., Heim, V. M., Lathrop, C. A., Rebustini, I. T., Stewart, J. S., Larsen, M., and Hoffman, M. P. (2005) Development (Camb.) 132, 1223–1234[Abstract/Free Full Text]
  57. Arman, E., Haffner-Krausz, R., Gorivodsky, M., and Lonai, P. (1999) Proc. Natl. Acad. Sci., U. S. A. 96, 11895–11899[Abstract/Free Full Text]
  58. Sekine, K., Ohuchi, H., Fujiwara, M., Yamasaki, M., Yoshizawa, T., Sato, T., Yagishita, N., Matsui, D., Koga, Y., Itoh, N., and Kato, S. (1999) Nat. Genet. 21, 138–141[CrossRef][Medline] [Order article via Infotrieve]
  59. Park, W. Y., Miranda, B., Lebeche, D., Hashimoto, G., and Cardoso, W. V. (1998) Dev. Biol. 201, 125–134[CrossRef][Medline] [Order article via Infotrieve]
  60. Bellusci, S., Grindley, J., Emoto, H., Itoh, N., and Hogan, B. L. (1997) Development (Camb.) 124, 4867–4878[Abstract]
  61. Burns, R. C., Fairbanks, T. J., Sala, F., De Langhe, S., Mailleux, A., Thiery, J. P., Dickson, C., Itoh, N., Warburton, D., Anderson, K. D., and Bellusci, S. (2004) Dev. Biol. 265, 61–74[CrossRef][Medline] [Order article via Infotrieve]
  62. Rice, R., Spencer-Dene, B., Connor, E. C., Gritli-Linde, A., McMahon, A. P., Dickson, C., Thesleff, I., and Rice, D. P. (2004) J. Clin. Investig. 113, 1692–1700[CrossRef][Medline] [Order article via Infotrieve]
  63. Cohen, M. M. J. (2000) in Craniosynostosis, Diagnosis, Evaluation, and Management (Cohen, M. M. J., and MacLean, R. E., eds) 2nd Ed., Oxford University Press, New York
  64. Cohen, M. M., Jr., and Kreiborg, S. (1990) Am. J. Med. Genet. 35, 36–45[CrossRef][Medline] [Order article via Infotrieve]
  65. Cohen, M. M., Jr., and Kreiborg, S. (1995) Am. J. Med. Genet. 57, 82–96[CrossRef][Medline] [Order article via Infotrieve]
  66. Yu, K., and Ornitz, D. M. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 3641–3643[Free Full Text]
  67. Yu, K., Herr, A. B., Waksman, G., and Ornitz, D. M. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 14536–14541[Abstract/Free Full Text]
  68. Ibrahimi, O. A., Chiu, E. S., McCarthy, J. G., and Mohammadi, M. (2005) Plast. Reconstr. Surg. 115, 264–270[Medline] [Order article via Infotrieve]
  69. Ibrahimi, O. A., Eliseenkova, A. V., Plotnikov, A. N., Yu, K., Ornitz, D. M., and Mohammadi, M. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 7182–7187[Abstract/Free Full Text]
  70. Olsen, S. K., Li, J. Y., Bromleigh, C., Eliseenkova, A. V., Ibrahimi, O. A., Lao, Z., Zhang, F., Linhardt, R. J., Joyner, A. L., and Mohammadi, M. (2006) Genes Dev. 20, 185–198[Abstract/Free Full Text]
  71. Maruoka, Y., Ohbayashi, N., Hoshikawa, M., Itoh, N., Hogan, B. M., and Furuta, Y. (1998) Mech. Dev. 74, 175–177[CrossRef][Medline] [Order article via Infotrieve]
  72. Xu, J., Lawshe, A., MacArthur, C. A., and Ornitz, D. M. (1999) Mech. Dev. 83, 165–178[CrossRef][Medline] [Order article via Infotrieve]
  73. Ohbayashi, N., Hoshikawa, M., Kimura, S., Yamasaki, M., Fukui, S., and Itoh, N. (1998) J. Biol. Chem. 273, 18161–18164[Abstract/Free Full Text]
  74. Sato, T., Joyner, A. L., and Nakamura, H. (2004) Dev. Growth Differ. 46, 487–494[CrossRef][Medline] [Order article via Infotrieve]
  75. Liu, A., Li, J. Y., Bromleigh, C., Lao, Z., Niswander, L. A., and Joyner, A. L. (2003) Development (Camb.) 130, 6175–6185[Abstract/Free Full Text]
  76. Martinez, S., Crossley, P. H., Cobos, I., Rubenstein, J. L., and Martin, G. R. (1999) Development (Camb.) 126, 1189–1200[Abstract]
  77. Lewandoski, M., Sun, X., and Martin, G. R. (2000) Nat. Genet. 26, 460–463[CrossRef][Medline] [Order article via Infotrieve]
  78. Liu, Z., Xu, J., Colvin, J. S., and Ornitz, D. M. (2002) Genes Dev. 16, 859–869[Abstract/Free Full Text]
  79. Ohbayashi, N., Shibayama, M., Kurotaki, Y., Imanishi, M., Fujimori, T., Itoh, N., and Takada, S. (2002) Genes Dev. 16, 870–879[Abstract/Free Full Text]
  80. Zhang, X., Stappenbeck, T. S., White, A. C., Lavine, K. J., Gordon, J. I., and Ornitz, D. M. (2006) Development (Camb.) 133, 173–180[Abstract/Free Full Text]
  81. Lavine, K. J., Yu, K., White, A. C., Zhang, X., Smith, C., Partanen, J., and Ornitz, D. M. (2005) Dev. Cell 8, 85–95[CrossRef][Medline] [Order article via Infotrieve]
  82. Pirvola, U., Zhang, X., Mantela, J., Ornitz, D. M., and Ylikoski, J. (2004) Dev. Biol. 273, 350–360[CrossRef][Medline] [Order article via Infotrieve]
  83. Schmahl, J., Kim, Y., Colvin, J. S., Ornitz, D. M., and Capel, B. (2004) Development (Camb.) 131, 3627–3636[Abstract/Free Full Text]
  84. Colvin, J. S., White, A., Pratt, S. J., and Ornitz, D. M. (2001) Development (Camb.) 128, 2095–2106[Abstract/Free Full Text]
  85. Colvin, J. S., Feldman, B., Nadeau, J. H., Goldfarb, M., and Ornitz, D. M. (1999) Dev. Dyn. 216, 72–88[CrossRef][Medline] [Order article via Infotrieve]
  86. Colvin, J. S., Green, R. P., Schmahl, J., Capel, B., and Ornitz, D. M. (2001) Cell 104, 875–889[CrossRef][Medline] [Order article via Infotrieve]
  87. Dinapoli, L., Batchvarov, J., and Capel, B. (2006) Development (Camb.) 133, 1519–1527[Abstract/Free Full Text]
  88. White, A. C., Xu, J., Yin, Y., Smith, C., Schmid, G., and Ornitz, D. M. (2006) Development (Camb.) 133, 1507–1517[Abstract/Free Full Text]
  89. Benet-Pages, A., Orlik, P., Strom, T. M., and Lorenz-Depiereux, B. (2005) Hum. Mol. Genet. 14, 385–390[Abstract/Free Full Text]
  90. Kobayashi, K., Imanishi, Y., Miyauchi, A., Onoda, N., Kawata, T., Tahara, H., Goto, H., Miki, T., Ishimura, E., Sugimoto, T., Ishikawa, T., Inaba, M., and Nishizawa, Y. (2006) Eur. J. Endocrinol. 154, 93–99[Abstract/Free Full Text]
  91. Kobayashi, K., Imanishi, Y., Koshiyama, H., Miyauchi, A., Wakasa, K., Kawata, T., Goto, H., Ohashi, H., Koyano, H. M., Mochizuki, R., Miki, T., Inaba, M., and Nishizawa, Y. (2005) Life Sci. 78, 2295–2301
  92. Shimada, T., Hasegawa, H., Yamazaki, Y., Muto, T., Hino, R., Takeuchi, Y., Fujita, T., Nakahara, K., Fukumoto, S., and Yamashita, T. (2004) J. Bone Miner. Res. 19, 429–435[CrossRef][Medline] [Order article via Infotrieve]
  93. Strewler, G. J. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 5945–5946[Free Full Text]
  94. Larsson, T., Marsell, R., Schipani, E., Ohlsson, C., Ljunggren, O., Tenenhouse, H. S., Juppner, H., and Jonsson, K. B. (2004) Endocrinology 145, 3087–3094[Abstract/Free Full Text]
  95. Kurosu, H., Ogawa, Y., Miyoshi, M., Yamamoto, M., Nandi, A., Rosenblatt, K. P., Baum, M. G., Schiavi, S., Hu, M. C., Moe, O. W., and Kuro-o, M. (2006) J. Biol. Chem 281, 6120–6123[Abstract/Free Full Text]
  96. Yan, X., Yokote, H., Jing, X., Yao, L., Sawada, T., Zhang, Y., Liang, S., and Sakaguchi, K. (2005) Genes Cells 10, 489–502[Abstract/Free Full Text]
  97. Smallwood, P. M., Munoz-Sanjuan, I., Tong, P., Macke, J. P., Hendry, S. H., Gilbert, D. J., Copeland, N. G., Jenkins, N. A., and Nathans, J. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 9850–9857[Abstract/Free Full Text]
  98. Verdier, A. S., Mattei, M. G., Lovec, H., Hartung, H., Goldfarb, M., Birnbaum, D., and Coulier, F. (1997) Genomics 40, 151–154[CrossRef][Medline] [Order article via Infotrieve]
  99. Coulier, F., Pontarotti, P., Roubin, R., Hartung, H., Goldfarb, M., and Birnbaum, D. (1997) J. Mol. Evol. 44, 43–56[CrossRef][Medline] [Order article via Infotrieve]
  100. Hartung, H., Feldman, B., Lovec, H., Coulier, F., Birnbaum, D., and Goldfarb, M. (1997) Mech. Dev. 64, 31–39[CrossRef][Medline] [Order article via Infotrieve]
  101. Wang, Q., McEwen, D. G., and Ornitz, D. M. (2000) Mech. Dev. 90, 283–287[CrossRef][Medline] [Order article via Infotrieve]
  102. Dalski, A., Atici, J., Kreuz, F. R., Hellenbroich, Y., Schwinger, E., and Zuhlke, C. (2005) Eur. J. Hum. Genet. 13, 118–120[CrossRef][Medline] [Order article via Infotrieve]
  103. Van Swieten, J. C., Brusse, E., De Graaf, B. M., Krieger, E., Van De Graaf, R., De Koning, I., Maat-Kievit, A., Leegwater, P., Dooijes, D., Oostra, B. A., and Heutink, P. (2003) Am. J. Hum. Genet. 72, 191–199[CrossRef][Medline] [Order article via Infotrieve]
  104. Wang, Q., Bardgett, M. E., Wong, M., Wozniak, D. F., Lou, J., McNeil, B. D., Chen, C., Nardi, A., Reid, D. C., Yamada, K., and Ornitz, D. M. (2002) Neuron 35, 25–38[CrossRef][Medline] [Order article via Infotrieve]
  105. Schoorlemmer, J., and Goldfarb, M. (2002) J. Biol. Chem. 277, 49111–49119[Abstract/Free Full Text]
  106. Wittmack, E. K., Rush, A. M., Craner, M. J., Goldfarb, M., Waxman, S. G., and Dib-Hajj, S. D. (2004) J. Neurosci. 24, 6765–6775[Abstract/Free Full Text]
  107. Liu, C., Dib-Hajj, S. D., and Waxman, S. G. (2001) J. Biol. Chem. 276, 18925–18933[Abstract/Free Full Text]
  108. Liu, C. J., Dib-Hajj, S. D., Renganathan, M., Cummins, T. R., and Waxman, S. G. (2003) J. Biol. Chem. 278, 1029–1036[Abstract/Free Full Text]
  109. Lou, J. Y., Laezza, F., Gerber, B. R., Xiao, M., Yamada, K. A., Hartmann, H., Craig, A. M., Nerbonne, J. M., and Ornitz, D. M. (2005) J. Physiol. (Lond.) 569, 179–193[Abstract/Free Full Text]
  110. Olsen, S. K., Ibrahimi, O. A., Raucci, A., Zhang, F., Eliseenkova, A. V., Yayon, A., Basilico, C., Linhardt, R. J., Schlessinger, J., and Mohammadi, M. (2004) Proc. Natl. Acad. Sci. U. S. A. 101, 935–940[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Mol. Cell. Biol.Home page
J.-H. Seo, A. Suenaga, M. Hatakeyama, M. Taiji, and A. Imamoto
Structural and Functional Basis of a Role for CRKL in a Fibroblast Growth Factor 8-Induced Feed-Forward Loop
Mol. Cell. Biol., June 1, 2009; 29(11): 3076 - 3087.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. C. Tomlinson, F. R. Lamont, S. D. Shnyder, and M. A. Knowles
Fibroblast Growth Factor Receptor 1 Promotes Proliferation and Survival via Activation of the Mitogen-Activated Protein Kinase Pathway in Bladder Cancer
Cancer Res., June 1, 2009; 69(11): 4613 - 4620.
[Abstract] [Full Text] [PDF]

Home page
 J ANIM SCIHome page
J. A. Grado-Ahuir, P. Y. Aad, G. Ranzenigo, F. Caloni, F. Cremonesi, and L. J. Spicer
Microarray analysis of insulin-like growth factor-I-induced changes in messenger ribonucleic acid expression in cultured porcine granulosa cells: Possible role of insulin-like growth factor-I in angiogenesis
J Anim Sci, June 1, 2009; 87(6): 1921 - 1933.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
Y. Ueda, Y. Karasawa, Y. Satoh, S. Nishikawa, J. Imaki, and M. Ito
Purification and Characterization of Mouse Lacrimal Gland Epithelial Cells and Reconstruction of an Acinarlike Structure in Three-Dimensional Culture
Invest. Ophthalmol. Vis. Sci., May 1, 2009; 50(5): 1978 - 1987.
[Abstract] [Full Text] [PDF]

Home page
 DevelopmentHome page
S. Kadam, A. McMahon, P. Tzou, and A. Stathopoulos
FGF ligands in Drosophila have distinct activities required to support cell migration and differentiation
Development, March 1, 2009; 136(5): 739 - 747.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
D J Mulder, I Pacheco, D J Hurlbut, N Mak, G T Furuta, R J MacLeod, and C J Justinich
FGF9-induced proliferative response to eosinophilic inflammation in oesophagitis
Gut, February 1, 2009; 58(2): 166 - 173.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
K. J. Lavine and D. M. Ornitz
Shared Circuitry: Developmental Signaling Cascades Regulate Both Embryonic and Adult Coronary Vasculature
Circ. Res., January 30, 2009; 104(2): 159 - 169.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
S. L. Mansour, S. R.F. Twigg, R. M. Freeland, S. A. Wall, C. Li, and A. O.M. Wilkie
Hearing loss in a mouse model of Muenke syndrome
Hum. Mol. Genet., January 1, 2009; 18(1): 43 - 50.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H. Umemori and J. R. Sanes
Signal Regulatory Proteins (SIRPS) Are Secreted Presynaptic Organizing Molecules
J. Biol. Chem., December 5, 2008; 283(49): 34053 - 34061.
[Abstract] [Full Text] [PDF]

Home page
 DevelopmentHome page
E. J. Park, Y. Watanabe, G. Smyth, S. Miyagawa-Tomita, E. Meyers, J. Klingensmith, T. Camenisch, M. Buckingham, and A. M. Moon
An FGF autocrine loop initiated in second heart field mesoderm regulates morphogenesis at the arterial pole of the heart
Development, November 1, 2008; 135(21): 3599 - 3610.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
D. Bonneh-Barkay, S. J. Bissel, G. Wang, K. N. Fish, G. C.B. Nicholl, S. W. Darko, R. Medina-Flores, M. Murphey-Corb, P. A. Rajakumar, J. Nyaundi, et al.
YKL-40, a Marker of Simian Immunodeficiency Virus Encephalitis, Modulates the Biological Activity of Basic Fibroblast Growth Factor
Am. J. Pathol., July 1, 2008; 173(1): 130 - 143.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Mori, C.-Y. Wu, S. Yamaji, J. Saegusa, B. Shi, Z. Ma, Y. Kuwabara, K. S. Lam, R. R. Isseroff, Y. K. Takada, et al.
Direct Binding of Integrin {alpha}v{beta}3 to FGF1 Plays a Role in FGF1 Signaling
J. Biol. Chem., June 27, 2008; 283(26): 18066 - 18075.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. Dutt, H. B. Salvesen, T.-H. Chen, A. H. Ramos, R. C. Onofrio, C. Hatton, R. Nicoletti, W. Winckler, R. Grewal, M. Hanna, et al.
Drug-sensitive FGFR2 mutations in endometrial carcinoma
PNAS, June 24, 2008; 105(25): 8713 - 8717.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
T. Hayashi, C. A. Ray, and O. Bermingham-McDonogh
Fgf20 Is Required for Sensory Epithelial Specification in the Developing Cochlea
J. Neurosci., June 4, 2008; 28(23): 5991 - 5999.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. J. Goodger, C. J. Robinson, K. J. Murphy, N. Gasiunas, N. J. Harmer, T. L. Blundell, D. A. Pye, and J. T. Gallagher
Evidence That Heparin Saccharides Promote FGF2 Mitogenesis through Two Distinct Mechanisms
J. Biol. Chem., May 9, 2008; 283(19): 13001 - 13008.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
S. Y. Lu, D. P. Sontag, K. A. Detillieux, and P. A. Cattini
FGF-16 is released from neonatal cardiac myocytes and alters growth-related signaling: a possible role in postnatal development
Am J Physiol Cell Physiol, May 1, 2008; 294(5): C1242 - C1249.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
M. Murakami, A. Elfenbein, and M. Simons
Non-canonical fibroblast growth factor signalling in angiogenesis
Cardiovasc Res, May 1, 2008; 78(2): 223 - 231.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
N. Sugaya, H. Habuchi, N. Nagai, S. Ashikari-Hada, and K. Kimata
6-O-Sulfation of Heparan Sulfate Differentially Regulates Various Fibroblast Growth Factor-dependent Signalings in Culture
J. Biol. Chem., April 18, 2008; 283(16): 10366 - 10376.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
V. N. Patel, K. M. Likar, S. Zisman-Rozen, S. N. Cowherd, K. S. Lassiter, I. Sher, E. A. Yates, J. E. Turnbull, D. Ron, and M. P. Hoffman
Specific Heparan Sulfate Structures Modulate FGF10-mediated Submandibular Gland Epithelial Morphogenesis and Differentiation
J. Biol. Chem., April 4, 2008; 283(14): 9308 - 9317.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Kunii, L. Davis, J. Gorenstein, H. Hatch, M. Yashiro, A. Di Bacco, C. Elbi, and B. Lutterbach
FGFR2-Amplified Gastric Cancer Cell Lines Require FGFR2 and Erbb3 Signaling for Growth and Survival
Cancer Res., April 1, 2008; 68(7): 2340 - 2348.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
M. Suzuki, Y. Uehara, K. Motomura-Matsuzaka, J. Oki, Y. Koyama, M. Kimura, M. Asada, A. Komi-Kuramochi, S. Oka, and T. Imamura
{beta}Klotho Is Required for Fibroblast Growth Factor (FGF) 21 Signaling through FGF Receptor (FGFR) 1c and FGFR3c
Mol. Endocrinol., April 1, 2008; 22(4): 1006 - 1014.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
D. Meijer, A. M Sieuwerts, M. P Look, T. van Agthoven, J. A Foekens, and L. C J Dorssers
Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer
Endocr. Relat. Cancer, March 1, 2008; 15(1): 101 - 111.
[Abstract] [Full Text] [PDF]

Home page
 DevelopmentHome page
M. A. Basson, D. Echevarria, C. Petersen Ahn, A. Sudarov, A. L. Joyner, I. J. Mason, S. Martinez, and G. R. Martin
Specific regions within the embryonic midbrain and cerebellum require different levels of FGF signaling during development
Development, March 1, 2008; 135(5): 889 - 898.
[Abstract] [Full Text] [PDF]

Home page
 DevelopmentHome page
K. Yu and D. M. Ornitz
FGF signaling regulates mesenchymal differentiation and skeletal patterning along the limb bud proximodistal axis
Development, February 1, 2008; 135(3): 483 - 491.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. Zhang, T. Sawada, X. Jing, H. Yokote, X. Yan, and K. Sakaguchi
Regulation of Ephexin1, a Guanine Nucleotide Exchange Factor of Rho Family GTPases, by Fibroblast Growth Factor Receptor-mediated Tyrosine Phosphorylation
J. Biol. Chem., October 19, 2007; 282(42): 31103 - 31112.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
Y. Kim, N. Bingham, R. Sekido, K. L. Parker, R. Lovell-Badge, and B. Capel
Fibroblast growth factor receptor 2 regulates proliferation and Sertoli differentiation during male sex determination
PNAS, October 16, 2007; 104(42): 16558 - 16563.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
X. Wu, H. Ge, J. Gupte, J. Weiszmann, G. Shimamoto, J. Stevens, N. Hawkins, B. Lemon, W. Shen, J. Xu, et al.
Co-receptor Requirements for Fibroblast Growth Factor-19 Signaling
J. Biol. Chem., October 5, 2007; 282(40): 29069 - 29072.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
X. Huang, C. Yang, Y. Luo, C. Jin, F. Wang, and W. L. McKeehan
FGFR4 Prevents Hyperlipidemia and Insulin Resistance but Underlies High-Fat Diet Induced Fatty Liver
Diabetes, October 1, 2007; 56(10): 2501 - 2510.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H. Kurosu, M. Choi, Y. Ogawa, A. S. Dickson, R. Goetz, A. V. Eliseenkova, M. Mohammadi, K. P. Rosenblatt, S. A. Kliewer, and M. Kuro-o
Tissue-specific Expression of betaKlotho and Fibroblast Growth Factor (FGF) Receptor Isoforms Determines Metabolic Activity of FGF19 and FGF21
J. Biol. Chem., September 14, 2007; 282(37): 26687 - 26695.
[Abstract] [Full Text] [PDF]

Home page
 J HeredHome page
J. S. Kehler, V. A. David, A. A. Schaffer, K. Bajema, E. Eizirik, D. K. Ryugo, S. S. Hannah, S. J. O'Brien, and M. Menotti-Raymond
Four Independent Mutations in the Feline Fibroblast Growth Factor 5 Gene Determine the Long-Haired Phenotype in Domestic Cats
J. Hered., September 1, 2007; 98(6): 555 - 566.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
J. Saarimaki-Vire, P. Peltopuro, L. Lahti, T. Naserke, A. A. Blak, D. M. Vogt Weisenhorn, K. Yu, D. M. Ornitz, W. Wurst, and J. Partanen
Fibroblast Growth Factor Receptors Cooperate to Regulate Neural Progenitor Properties in the Developing Midbrain and Hindbrain
J. Neurosci., August 8, 2007; 27(32): 8581 - 8592.
[Abstract] [Full Text] [PDF]

Home page
 DevelopmentHome page
K. Sugiura, Y.-Q. Su, F. J. Diaz, S. A. Pangas, S. Sharma, K. Wigglesworth, M. J. O'Brien, M. M. Matzuk, S. Shimasaki, and J. J. Eppig
Oocyte-derived BMP15 and FGFs cooperate to promote glycolysis in cumulus cells
Development, July 15, 2007; 134(14): 2593 - 2603.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
Y. Ogawa, H. Kurosu, M. Yamamoto, A. Nandi, K. P. Rosenblatt, R. Goetz, A. V. Eliseenkova, M. Mohammadi, and M. Kuro-o
betaKlotho is required for metabolic activity of fibroblast growth factor 21
PNAS, May 1, 2007; 104(18): 7432 - 7437.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
V. P. Eswarakumar and J. Schlessinger
Skeletal overgrowth is mediated by deficiency in a specific isoform of fibroblast growth factor receptor 3
PNAS, March 6, 2007; 104(10): 3937 - 3942.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
A. Kharitonenkov, V. J. Wroblewski, A. Koester, Y.-F. Chen, C. K. Clutinger, X. T. Tigno, B. C. Hansen, A. B. Shanafelt, and G. J. Etgen
The Metabolic State of Diabetic Monkeys Is Regulated by Fibroblast Growth Factor-21
Endocrinology, February 1, 2007; 148(2): 774 - 781.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
M. Timmer, K. Cesnulevicius, C. Winkler, J. Kolb, E. Lipokatic-Takacs, J. Jungnickel, and C. Grothe
Fibroblast Growth Factor (FGF)-2 and FGF Receptor 3 Are Required for the Development of the Substantia Nigra, and FGF-2 Plays a Crucial Role for the Rescue of Dopaminergic Neurons after 6-Hydroxydopamine Lesion
J. Neurosci., January 17, 2007; 27(3): 459 - 471.
[Abstract] [Full Text] [PDF]

Home page
 DevelopmentHome page
Y. Pan, A. Woodbury, J. D. Esko, K. Grobe, and X. Zhang
Heparan sulfate biosynthetic gene Ndst1 is required for FGF signaling in early lens development
Development, December 15, 2006; 133(24): 4933 - 4944.
[Abstract] [Full Text] [PDF]

Home page
 IBMS BoneKEyHome page
G. J. Strewler
Bone Talk: Klotho and FGF23 Signaling
IBMS BoneKEy, December 1, 2006; 3(12): 36 - 40.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
C. L. Chaffer, J. P. Brennan, J. L. Slavin, T. Blick, E. W. Thompson, and E. D. Williams
Mesenchymal-to-Epithelial Transition Facilitates Bladder Cancer Metastasis: Role of Fibroblast Growth Factor Receptor-2
Cancer Res., December 1, 2006; 66(23): 11271 - 11278.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
281/23/15694    most recent
M601252200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhang, X.
Right arrow Articles by Ornitz, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhang, X.
Right arrow Articles by Ornitz, D. M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2006 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement